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Background: MDC1A is a congenital neuromuscular disorder with developmentally complex and progressive
pathologies that results from a deficiency in the protein laminin α2. MDC1A is associated with a multitude of
pathologies, including increased apoptosis, inflammation and fibrosis. In order to assess and treat a complicated
disease such as MDC1A, we must understand the natural history of the disease so that we can identify early disease
drivers and pinpoint critical time periods for implementing potential therapies.
Results: We found that DyW mice show significantly impaired myogenesis and high levels of apoptosis as early as
postnatal week 1. We also saw a surge of inflammatory response at the first week, marked by high levels of
infiltrating macrophages, nuclear factor κB activation, osteopontin expression and overexpression of inflammatory
cytokines. Fibrosis markers and related pathways were also observed to be elevated throughout early postnatal
development in these mice, including periostin, collagen and fibronectin gene expression, as well as transforming
growth factor β signaling. Interestingly, fibronectin was found to be the predominant fibrous protein of the
extracellular matrix in early postnatal development. Lastly, we observed upregulation in various genes related to
angiotensin signaling.
Methods: We sought out to examine the dysregulation of various pathways throughout early development
(postnatal weeks 1-4) in the DyW mouse, the most commonly used mouse model of laminin-deficient muscular
dystrophy. Muscle function tests (stand-ups and retractions) as well as gene (qRT-PCR) and protein levels (western
blot, ELISA), histology (H&E, picrosirius red staining) and immunohistochemistry (fibronectin, TUNEL assay) were
used to assess dysregulation of matricelluar protieins.
Conclusions: Our results implicate the involvement of multiple signaling pathways in driving the earliest stages of
pathology in DyW mice. As opposed to classical dystrophies, such as Duchenne muscular dystrophy, the
dysregulation of various matricellular proteins appears to be a distinct feature of the early progression of DyW
pathology. On the basis of our results, we believe that therapies that may reduce apoptosis and stabilize the
homeostasis of extracellular matrix proteins may have increased efficacy if started at a very early age.
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The congenital muscular dystrophies (CMDs) are a highly
heterogeneous group of degenerative neuromuscular disor-
ders that arise primarily from defects in proteins within or
relating to the dystrophin–glycoprotein complex (DGC)
[1,2]. Merosin-deficient CMD type 1A (MDC1A) results
from a mutation in the α2 chain of laminin 211, an isoform
essential to skeletal muscle which is responsible for aiding
membrane stability and signal transduction across the
sarcolemma [3]. Absence of a functional copy of this pro-
tein results in severe dysregulation of a wide range of sig-
naling pathways, ultimately leading to apoptosis, failed
regeneration, chronic inflammation, fibrosis and muscle
wasting [4-8]. The effects manifest so early in life that pa-
tients with MDC1A present with profound muscle weak-
ness and hypotonia, either at or soon after birth, and rarely
achieve independent ambulation [9-11]. Children with this
disease typically die as a result of respiratory complications
or failure to thrive by their early teens [12]. Although great
strides have been made in research, no effective therapies
or treatments are available to patients with MDC1A.
One of the greatest problems researchers face is an es-
sential lack of understanding of how the various path-
ologies of this disease progress early in life. Because this
is a multifaceted, aggressive illness, causative and cor-
relative pathomechanisms must be discriminated at
early time points in order for effective treatments to be
developed. At this point, only a few studies have been
conducted in humans and in animal models of MDC1A
at very early time points in attempts to elucidate the
early pathomechanisms of this disease [13-18], and no
extensive natural history of MDC1A has been docu-
mented at a molecular level. Although quite a few re-
searchers have tested the efficacy of various drugs and
transgenic therapies in models of MDC1A, their reason-
ing for choosing those therapies often must be extrapo-
lated from research on Duchenne muscular dystrophy
(DMD). However, these two diseases have distinct de-
fects (one results from a defect in an intracellular pro-
tein, the other from an extracellular one) and must be
treated as such in the context of understanding the
pathomechanisms driving each disorder [19,20].
It has previously been demonstrated that patients with
MDC1A have stunted growth, limited regenerative cap-
acity and an early surge of inflammation followed by ex-
tensive fibrosis in the months soon after birth [18,21]. In
our present study, we used the Lama2DyW (DyW) mouse
model to recapitulate the human disease progression and
show that each of these pathologies, though consistently
present through postnatal development, are dynamic and
evolve in complexity over time. Using histological and bio-
chemical analyses at postnatal weeks 1, 2, 3 and 4, we ob-
served that the muscles of these mice exhibited very early
signs of elevated apoptosis and impaired myogenesis asearly as week 1. Most notably, we saw that the expression
of various matricellular proteins was dysregulated at the
first week after birth, which may help to shed light on the
nature of inflammation and fibrosis in this disease. We be-
lieve that those pathways causing the dysregulatation of
extracellular proteins earliest in development are part of
the etiology of the rapid progression of this disease and
may serve as the most relevant targets for early interven-
tion in MDC1A.
Methods
Animal breeding and care
All animals were housed at the Laboratory Animal Care
Charles River Campus of Boston University on a 12:12-
hour light–dark cycle. Food and water were provided ad
libitum. All procedures were performed in accordance to
the protocol approved by the Institutional Animal Care and
Use Committee of Boston University. Heterozygous B6.129
Lama2dy−W/+ (DyW) mice carrying a targeted mutation in
the Lama2 gene were kindly provided by Dr Eva Engvall
(Burnham Institute, La Jolla, CA, USA). Of the available
mouse models, the DyW mouse is the most widely used for
studying MDC1A pathology.
Muscle tissue collection
Animals were euthanized with isofluorane (Webster
Veterinary, Devens, MA, USA) before isolating the tibi-
alis anterior (TA), gastrocnemius–soleus complex (GS)
and quadriceps muscles (QD). Tissues were weighed and
snap-frozen in liquid nitrogen for RNA and protein
extraction. TA muscles used for histology were embed-
ded in Tissue-Tek OCT compound (Sakura Finetek
USA, Torrance, CA, USA) and frozen in isopentane
(Sigma-Aldrich, St Louis, MO, USA) chilled in liquid ni-
trogen. Serial transverse sections (7 μm) were prepared
using the Leica CM1850 cryostat (Leica Microsystems,
Buffalo Grove, IL, USA) and stored at −80°C.
Muscle histology
Frozen sections were air-dried at room temperature for
15 minutes and fixed in chilled acetone for 5 minutes. Sec-
tions were hydrated through decreasing grades of alcohol.
Midbelly cross-sections were stained with hematoxylin
(Fisher Scientific, Fair Lawn, NJ, USA) for 1 minute,
followed by development in 1% ammonium hydroxide for
1 minute. Sections were subsequently stained with Ruben’s
Eosin-Phloxine working solution (Fisher Scientific) for 2 mi-
nutes. After dehydration through increasing grades of alco-
hol and xylene, sections were mounted using Permount
mounting medium (Fisher Scientific). Picro-Sirius Red
(American MasterTech Scientific, Lodi, CA, USA) staining
of the sections, which had been fixed with acetone and
rehydrated was done according to the manufacturer’s in-
structions. Briefly, the sections were stained with Picro-
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twice in 0.5% acetic acid and then dehydrated with increas-
ing grades of alcohol and mounted in Permount medium.
A Nikon DS-Fi1 camera head attached to a Nikon
ECLIPSE 50i light microscope system (Nikon Instruments,
Melville, NY, USA) was used to capture images of stained
sections. Morphometric analyses were performed using
NIS-Elements Basic Research 3.0 software. Myofiber num-
ber and cross-sectional area were measured.
Immunohistochemistry
Frozen tissue sections were fixed in 2% paraformaldehyde
for 10 minutes, blocked for 60 minutes with 2% bovine
serum albumin, 2% goat serum and 0.1% Triton X-100 in
1× phosphate-buffered saline (PBS). For the Mac-1 stain,
slides were incubated with anti-CD11b antibody (1:200 di-
lution; BD Biosciences, San Jose, CA, USA) for 60 minutes
in the dark. For the fibronectin stain, slides were incubated
for 2 hours in anti-fibronectin antibody (catalog no. F7387;
Sigma-Aldrich) and then incubated in Alexa Fluor 488 goat
anti-mouse secondary antibodies in the dark for an add-
itional hour. Nuclei for both assays were stained with
0.1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI) for 5 mi-
nutes. After washing with PBS, sections were mounted with
VECTASHIELD mounting medium (catalog no. H1000;
Vector Laboratories, Burlingame, CA, USA).
TUNEL assay
Terminal deoxynucleotidyl transferase 2′-deoxyuridine-
5′-triphosphate nick-end labeling (TUNEL) staining of
the frozen muscle sections was done using ApopTag
Plus Fluorescein In Situ Apoptosis Detection Kit (catalog
no. S7111; EMD Millipore, Billerica, MA, USA;) as per
the manufacturer’s instructions. Briefly, the tissue sec-
tions were fixed in 1% paraformaldehyde and subse-
quently in acetic acid:ethyl alcohol (1:2 dilution) for
5 minutes each. The terminal deoxynucleotidyl transfer-
ase labeling was done for 60 minutes at 37°C, which was
followed by staining with anti-digoxigenin fluorescein
antibody for 30 minutes at room temperature. The sec-
tions were washed five times, for 2 minutes each time,
in PBS. Nuclear staining was done with 0.1 μg/ml DAPI
for 5 minutes. The sections were washed twice as de-
scribed above and mounted in VECTASHIELD mount-
ing medium. The sections were imaged using the Nikon
ECLIPSE 50i microscope system equipped with the
Nikon DS-Fi1 camera head. Images were analyzed using
Nikon NIS-Elements Basic Research 3.0 software.
Gene expression assay
RNA from 25 mg of snap-frozen hindlimb muscle tissues
was extracted with TRIzol reagent (catalog no. 15596-026;
Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. RNA (1 μg) was reverse-transcribedwith the High-Capacity cDNA Reverse Transcription Kit
(catalog no. 4368814; Applied Biosystems, Foster City, CA,
USA). Gene expression analysis was carried out using Taq-
Man gene expression assays (Applied Biosystems, Foster
City, CA, USA) on the Applied Biosystems 7300 Real-Time
PCR System. 18S ribosomal subunit RNA served as the en-
dogenous control, and gene expression was calculated by
using the comparative ΔΔCt threshold cycle method.
Western blot analysis
Five biological samples per animal group were pooled
for protein extraction. Muscle lysates were prepared by
homogenizing 25 mg of muscle in radioimmunoprecipita-
tion assay buffer containing a cOmplete Protease Inhibitor
Cocktail tablet (catalog no. 04 693 195 001; Roche Diag-
nostics GmbH, Mannheim, Germany) and a PhosSTOP
Phosphatase Inhibitor Cocktail tablet (catalog no. 04 906
837 001; Roche Diagnostics GmbH). Protein concentra-
tion was estimated by Bio-Rad DC Protein Assay (catalog
no. 500-0114-6; Bio-Rad Laboratories, Hercules, CA,
USA), and 35 μg of protein were resolved on a 10% SDS-
PAGE gel and transferred onto a nitrocellulose membrane
by semidry electrophoretic transfer (Trans-Blot SD; Bio-
Rad Laboratories). Membranes were blocked with Odyssey
blocking buffer (catalog no. 927-40000; LI-COR Biosci-
ences, Lincoln, NE, USA) and probed with primary anti-
bodies (phosphorylated Smad2/3 (phospho-Smad2/3),
catalog no. 9963; total p65, catalog no. 4764; PhosP65,
catalog no. 3033; Cell Signaling Technology, Danvers,
MA, USA; Smad7, catalog no. MAB2029; R&D Systems,
Minneapolis, MN, USA) and 1:5,000 anti-α-tubulin mouse
primary antibodies (catalog no. T9822; Sigma-Aldrich) at
4°C overnight. The blot was washed three times for 5 mi-
nutes each time with Tris-buffered saline containing 0.1%
Tween 20 and subsequently stained with 1:2,000 goat
anti-rabbit IRDye 800CW IgG2b and IRDye 680LT IgG2b
antibodies (catalog nos. 926-32352 and 926-68052, re-
spectively; LI-COR Biosciences). The blots were then
washed and scanned for analysis using an Odyssey infra-
red imaging system (LI-COR Biosciences). Each Western
blot experiment was repeated three times.
Hydroxyproline assay
Collagen content in the muscles was determined using a
hydroxyproline colorimetric assay kit (catalog no. K555-
100; BioVison, Milpitas, CA, USA) according to the
manufacturer’s instructions. Briefly, 25 mg of hindlimb
muscle tissues from DyW and wild-type (WT) animals
(n = 5) were pooled and extracted in 500 μl of distilled
water. The lysates were acid-hydrolyzed with HCl
(13 M) at 120°C for 3 hours. Equal amounts of lysates and a
series of hydroxyproline standards were dispensed in 96-well
enzyme-linked immunosorbent assay (ELISA) plates, evapo-
rated at 60°C and oxidized using perchloric acid. The
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by chromogenic reaction employing chloramine-T and
4-dimethylaminobenzaldehyde substrate. The absorbance
was read at 560 nm.
Cytokine enzyme-linked immunosorbent assay
The Amount of cytokines in the muscles was determined
using ELISA kits (tumor necrosis factor α (TNF-α), catalog
no. 88-7324, and monocyte chemotactic protein 1 (MCP-
1), catalog no. 88-7391, eBioscience, San Diego, CA, USA;
osteopontin, Promega, Madison, WI, USA) following the
manufacturer’s instructions. Briefly, 25 mg of pooled hind-
limb muscle tissues were lysed in 10 vol. of lysis buffer con-
taining protease and phosphatase inhibitor cocktails. The
lysates were incubated with the capture antibody for 3 hours
at room temperature. The wells were washed five times for
3 minutes each time and incubated with detection anti-
bodies for 2 hours at room temperature. The wells were
washed as described above and incubated with avidin–
horseradish peroxidase conjugates. The washing step was
repeated again as above and incubated with the substrate
for 15 minutes. The reactions were stopped subsequently
and the absorbance was recorded at 450 nm.
Statistics
Statistical analyses were performed using GraphPad Prism
6 software (GraphPad Software, La Jolla, CA, USA) and
included two-way analysis of variance (ANOVA) followed
by Tukey’s multiple comparison analysis as appropriate, as
well as unpaired two-tailed t-tests. Data are presented as
mean ± standard deviation.
Results
Laminin α2-deficient mice failed to develop in both body
and muscle weight starting at week 3
We began our characterization of this animal model by
tracking overall body and hindlimb muscle weights through-
out early postnatal development. DyW and WT mice had
similar body weights at 1 week (DyW: 4.51 ± 0.8 g, n = 8;
WT: 5.92 ± 1.10 g, n = 5) and 2 weeks (DyW: 5.83 ± 0.821,
n = 9; WT: 6.72 ± 0.52 g, n = 6) after birth (Figure 1A). WT
mice then underwent a substantial growth spurt between
weeks 2 and 4 (3 weeks: 12.54 ± 2.54 g; 4 weeks: 17.43 ±
1.91 g; P < 0.001 by two-way ANOVA (n = 6 to 10)),
whereas DyW mice failed to substantially grow (3 weeks:
6.53 ± 1.83 g, 4 weeks: 7.76 ± 2.15 g). It should be noted
that other research groups saw statistical differences in
body size at postnatal day 7, though these differences were
still small [17].
We next determined whether this lack of early growth
correlates directly with muscle mass. Weights from the
TA, GS and QD muscles followed a pattern similar to that
of overall body weight (Figures 1B through 1D). Between 2
and 4 weeks, the hindlimb muscles from the WT miceunderwent a substantial growth spurt (at 2 weeks, TA:
6.92 ± 0.70 mg, GS: 20.8 ± 1.99 mg and QD: 23.2 ± 1.99 mg;
at 3 weeks, TA: 17.65 ± 2.75 mg, GS: 61.7 ± 7.28 mg and
QD: 59.76 ± 10.78 mg; at 4 weeks, TA: 24.025 ± 2.65 mg,
GS: 78.53 ± 8.39 mg, QD: 87.27 ± 8.74 mg; P < 0.0001 by
two-way ANOVA (n = 5 to 10)), which is greatly dampened
in DyW mice. The TA muscles of DyW animals showed a
significant increase between weeks 2 and 3 (4.32 ± 0.96 mg
to 7.98 ± 1.57 mg; P < 0.01 (n = 8 to 9)), whereas the GS
and QD muscles showed a significant weight gain between
weeks 1 and 3 (GS: 13.13 ± 2.61 mg to 21.66 ± 6.81 mg,
QD: 15.76 ± 2.99 mg to 34.1 ± 9.22 mg). Even though the
DyW hindlimb muscles underwent a small growth spurt,
they did not achieve nearly the same level of growth.
DyW muscles began to show histopathology as early as
postnatal day 1
We next used hematoxylin and eosin staining of frozen
TA muscle sections to look at the disease progression on
the cellular level. As early as postnatal day 1, DyW mice
exhibited obvious pathological symptoms marked by
large interstitial spaces filled with infiltrating mononu-
cleated cells, inconsistently sized myofibers and a lack of
delineation of fascicles (Figure 2A). As these mice aged,
their muscle fibers hypertrophied to a certain extent and
occupied more of the total muscle area. However, large
interstitial spaces and inconsistent fiber sizes persisted
through week 4.
Interestingly, even though dystrophic mice showed
obvious signs of muscle pathology at day 1, there was
no discernible difference in the cross-sectional area
(CSA) of their TA muscles compared to the WT mice
(DyW: 0.393 ± 0.061 mm2, WT: 0.472 ± 0.076 mm2)
(Figure 2B). However, beginning at postnatal week 3,
DyW muscles had significantly smaller muscle cross-
sections compared to age-matched WT muscles (3 weeks:
DyW: 2.06 ± 0.46 mm2, WT: 3.94 ± 0.48 mm2; 4 weeks:
DyW: 2.08 ± 0.51 mm2, WT: 4.86 ± 0.33 mm2; P < 0.0001
by two-way ANOVA (n = 3 to 5)). This follows a temporal
trend similar to observed in the muscle and body weights,
with WT mice showing a large growth spurt between
weeks 2 and 3 (P < 0.0001 by two-way ANOVA (n = 3-4))
and DyW muscles failing to show much growth.
Interestingly, even though CSA and muscle weights
were comparable between DyW and WT mice until post-
natal week 2, dystrophic TA muscles contained roughly
half the number of matured myofibers as early as week 1
(DyW: 1,265.25 ± 199.04, WT: 2,504 ± 129.64; P < 0.0001
by two-way ANOVA (n = 3 to 5)) (Figure 2C). DyW mus-
cles had a small but significant decrease in total fiber
number between weeks 1 and 2 (P < 0.05 by two-way
ANOVA (n = 4 to 5)), whereas WT mice showed a signifi-
cant increase in the number of myofibers during the same
time frame (P = 0.001 by two-way ANOVA (n = 3 or 4).
Figure 1 Overall body and isolated hindlimb muscle weights show limited growth in DyW mice during postnatal development. (A)
At postnatal weeks 1 and 2, Lama2DyW (DyW) mice had body weights to comparable those of wild-type (WT) mice, but were significantly smaller
starting at week 3 (P < 0.05 by t-test (n = 5 to 10). (B) Tibialis anterior (TA), (C) gastrocnemius/soleus (GS) and (D) quadriceps (QD) muscles of DyW mice
were also significantly smaller in weight compared to WT mice starting from 3 weeks of age (P < 0.0005 by analysis of variance (n = 6 to 10)). Asterisks
indicate statistical significance between age-matched DyW and WT animals; hash tags indicate statistically significant changes within the DyW group;
Delta indicates statistically significant changes within the WT group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. These statistical representations
also apply to the other symbols (Δ, #).
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after week 2 (3 weeks: DyW: 1,118 ± 82.6, WT: 2,968.67 ±
144.81; 4 weeks: DyW: 1,069 ± 61.77,WT: 3,132.33 ± 68.62).
DyW mice had increased incidence of apoptosis and
expression of myogenic markers throughout postnatal
development
TUNEL staining of TA muscle sections showed that there
was an elevated number of apoptotic nuclei in DyW ani-
mals throughout the early development time points. Rep-
resentative images of 2- and 4-week-old animals are
shown in Figure 3A. We demonstrate that both maturemuscle fibers and cells within the interstitium undergo
apoptosis in these tissues. Importantly, we observed that
at earlier time points, a subset of those TUNEL-positive
nuclei in the interstitial space are also desmin-positive
(one of the earliest markers for differentiated myogenic
cells). This is in contrast to older tissues, where TUNEL-
positive nuclei were mostly limited to the mature myofibers
and desmin-negative interstitial cells. Quantitation of
TUNEL-positive nuclei shows that apoptosis was signifi-
cantly increased in the DyW mice compared to the WT
mice at all time points (P < 0.001 by two-way ANOVA (n =
3)) and also that it was most abundant in DyW mice at
Figure 2 Qualitative and quantitative analysis of hematoxylin and eosin–stained tibialis anterior muscle sections show pathology as
early as 1 week of age. (A) Qualitative histological analyses of tibialis anterior (TA) muscles show pathogenesis beginning as early as 1 day of
age in Lama2DyW (DyW) mice. These muscles have large interstitial spaces filled with infiltrating mononucleated cells. Additionally, the muscles
tend to lack both consistent fiber sizes and a hierarchical organization of connective tissue. (B) Cross-sectional area measurements show limited
growth in DyW mice compared to wild-type (WT) mice during the first 4 weeks of life. WT mice have significantly larger muscle cross-sections at
weeks 3 and 4 compared to DyW mice (P < 0.0001 by two-way analysis of variance (ANOVA) (n = 3 to 5)). (C) Counts of the total number of
muscle fibers indicate that, as early as postnatal day 1, DyW mice already had a decreased number of muscle cells and that this number increased
during development. At all time points, DyW mice had significantly fewer myofibers than their WT counterparts (P < 0.0001 by two-way ANOVA
(n = 3 to 5). Note that, though the cross-sectional area does not indicate a diference at week 1, pathology is reflected in the fiber count. Asterisks
indicate statistical significance between age-matched DyW and WT animals, hash tags indicate significant changes within the DyW group and
Deltas indicate significant changes within the WT group. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. These statistical representations also
apply other symbols (Δ, #). Bar = 50 μm.
Mehuron et al. Skeletal Muscle 2014, 4:14 Page 6 of 18
http://www.skeletalmusclejournal.com/content/4/1/14weeks 1 and 2 and became less prevalent by weeks 3 and 4
(P < 0.0001 by two-way ANOVA (n = 3)) (Figure 3B).
We observed few TUNEL-positive nuclei in the WT
mice in the first 2 weeks and virtually none at subse-
quent time points.
To determine whether DyW muscles attempt to com-
pensate for lost muscle cells through upregulation of the
myogenic program, we looked at the gene expression of
MyoD, myogenin and embryonic myosin heavy chain
(eMYHC, myosin heavy chain 3 (MYH3)) as markers of
myogenesis. In these gene expression studies, we used 1-
week WT values for normalization throughout postnatal
development. Comparing the expression of all groups to
the WT at a single time point allowed us to observe
changes in both healthy and dystrophic animals over time,
which told us not only whether DyW mice had dysregu-
lated gene expression compared to age-matched WT, but
also how they vary from normal developmental progres-
sion. See Additional file 1: Table S1 for data concerning
DyW expression levels relative to age-matchedWT mice.WT mice expressed their highest levels of MyoD, myo-
genin and MYH3 at postnatal week 1, which then de-
creased with age. MyoD expression was significantly lower
in both groups by week 3 compared to week 1 (P < 0.0001
for WT and P < 0.001 for DyW by two-way ANOVA (n = 5
for all groups)) (Figure 3B). Myogenin showed a similar
but sharper decrease in expression between weeks 2 and 3
(P < 0.0001 by two-way ANOVA (n = 5)) (Figure 3C). At
all four time points, both myogenin and MyoD were sig-
nificantly upregulated in DyW muscle compared to age-
matched WT muscle (Additional file 1: Table S1) (1 week:
P < 0.05, 2 and 4 weeks: P < 0.001, 3 weeks: P < 0.0001, all
by two-way ANOVA (n = 5 for all groups)). Expression
of eMYHC in WT muscles was elevated at week 1,
followed by a sharp decrease by week 2 (P < 0.001 by
two-way ANOVA (n = 5), which remained low through
week 4 (Figure 3D). In contrast, eMYHC gene expression
was markedly higher in the DyW muscles at all time
points compared to age-matched WT muscles (P < 0.0005
at week 1, P < 0.0001 at weeks 2 and 4 and P < 0.005 at
Figure 3 (See legend on next page.)
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Figure 3 Gene expression analysis using quantitative RT-PCR, along with TUNEL immunostaining, show an increase in the myogenic
program and cell death. (A) Terminal deoxynucleotidyl transferase 2′-deoxyuridine-5′-triphosphate nick-end labeling (TUNEL) staining shows an
increased number of apoptotic nuclei in Lama2DyW (DyW) muscles at each of the four time points. Desmin costaining was used to delineate
differentiated myogenic cells. Arrows point to those cells that are both desmin-positive (red) and TUNEL-positive (green). (DyW is also referred to
as KO, Knockout.) (B) Quantitative analysis of the TUNEL staining shows the highest incidence of apoptosis at postnatal week 1, which decreased
by 50% at week 3. (C) Gene analysis of MyoD shows the highest expression for both groups early in life, followed by decreases over time. DyW
mice had significantly increased expression compared to age-matched wild-type (WT) mice at all time points (1 week: P < 0.05, 2 weeks: P < 0.001,
3 weeks: P < 0.0001 and 4 weeks: P < 0.001, all by two-way analysis of variance (ANOVA) (n = 5 for all groups). (D) Myogenin expression shows a
similar trend of having the highest expression early on, and DyW levels were also increased compared to all age-matched WT groups (1 week:
P < 0.01, 2 weeks: P < 0.0001, 3 weeks: P < 0.005 and 4 weeks: P < 0.0001, all by two-way ANOVA (n = 5 for all groups). (E) Embryonic myosin heavy
chain (eMYHC) expression was significantly elevated in the DyW mice at each of the four time points (1 week: P < 0.0005, 2 weeks: P < 0.0001,
3 weeks: P < 0.005 and 4 weeks: P < 0.0001, all by two-way ANOVA (n = 5). Asterisks indicate statistical significance between age-matched DyW
and WT animals, hash tags indicate significant changes within the DyW group and Deltas indicate significant changes within the WT group.
*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. These statistical representations also apply other symbols (Δ, #). Bar = 100 μm.
Figure 4 Mac-1 staining and quantitative RT-PCR of CD11b show elevated macrophage infiltration throughout postnatal development.
(A) Mac-1 immunostaining of tibialis anterior muscle sections shows high macrophage infiltration as early as postnatal week 1 in Lama2DyW (DyW)
mice. Wild-type (WT) mice had minimal macrophage presence at weeks 1 and 2 and virtually none by weeks 3 and 4. (B) Confirmation of these
results by CD11b quantitative RT-PCR shows consistent seven- to elevenfold increases in expression compared to age-matched WT (P < 0.0001 by
two-way analysis of variance for all groups (n = 5 for all groups)). Asterisks indicate statistical significance between age-matched DyW and WT
animals, hash tags indicate significant changes within the DyW group and Delta indicate significant changes within the WT group. *P < 0.05,
**P < 0.01, ***P < 0.001 and ****P < 0.0001. These statistical representations also apply other symbols (Δ, #). Bar =100 μm.
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Table S1). It is important to note that though this upregu-
lation was only twofold at week 1, this increase was over
thirty-fold by week 4.
Persistent macrophage infiltration was observed as early
as postnatal week 1 in DyW muscle
Immunostaining of TA muscle sections with Mac-1 anti-
body (CD11b, a marker for macrophages) revealed that
WT muscles had a limited number of macrophages at
week 1, a sparse presence by week 2 and virtually none by
weeks 3 and 4 (Figure 4A). Conversely, DyW mice had a
high level of macrophage infiltration as early as 1 week of
age, which continued throughout postnatal development.
Quantitative RT-PCR analysis confirmed these results by
showing increased expression of CD11b at all time points
(P < 0.0001 by two-way ANOVA (n = 5)) (Figure 4B).
DyW muscles showed a dynamic inflammatory
environment beginning at week 1
We have previously shown that nuclear factor κB (NF-κB),
and, more specifically, the activation of its p65 subunit, is
upregulated at week 8 in DyW animals [19]. To see if this
dysregulation is evident at earlier time points, we per-
formed Western blot analysis of p65 and phospho-p65. We
saw elevated levels of phospho-p65 (1.4-fold) as early as
postnatal week 1, though we observed no change in total
p65 (Figure 5A, Full blot can be found in Additional file 2).
To further explore the extent of inflammation in these
mice, we looked at the expression of various inflamma-
tory genes, beginning with the NF-κB-related cytokine
TNF-α (Figure 5B). In WT development, there was no
observed variation in expression between postnatal
weeks 1 and 4. Within the DyW group, there was a sig-
nificant decrease in TNF-α expression between weeks 1
and 2 (P < 0.001 by two-way ANOVA (n = 5), followed
by no significant expression changes through week 4.
However, DyW mice exhibited significantly elevated
TNF-α expression at week 1 (P < 0.01), week 3 (P <
0.0001) and week 4 (P < 0.05, all by two-way ANOVA)
(n = 5) compared to age-matched WT. Interestingly,
MCP-1, another NF-κB-related cytokine, became upreg-
ulated only at postnatal week 4 (P < 0.0001 by two-way
ANOVA (n = 5)) (Figure 5C). Osteopontin (a gene asso-
ciated with the inflammatory environment of dystrophic
mice which has been shown to have a correlation with
muscle scarring) showed massive upregulation in DyW
mice at all time points (P < 0.0001 by two-way ANOVA
(n = 5)) (Figure 5D). DyW animals had a nearly 100-fold
increase in osteopontin expression over the WT mice at
week 1, which significantly decreased by week 4 (P <
0.05 by two-way ANOVA (n = 5)). WT mice had no sig-
nificant changes in osteopontin expression between any
time points.ELISAs also revealed upregulation of these inflamma-
tory markers on the protein level. Although we saw the
greatest upregulation of TNF-α gene expression at post-
natal week 1, we actually did not see any change in pro-
tein levels compared to the WT mice at this time point
(Figure 5E). However, we did find protein expression of
TNF-α to be increased between 1.3- and 1.7-fold in
DyW animals throughout the rest of early postnatal devel-
opment (2 weeks: P < 0.05, and 3 and 4 weeks: P < 0.0001,
both by two-way ANOVA (n = 5)). Additionally, though we
did not see an increase in MCP-1 mRNA before postnatal
week 4, we saw a 1.9-fold upregulation in the protein as
early as week 2, which then remained elevated through
week 4 (P < 0001 by two-way ANOVA (n = 5) for all time
points) (Figure 5F). Similar to what we saw in gene ex-
pression, osteopontin protein was upregulated at all
time points, with the greatest increases seen at weeks 1,
2 and 3 (P < 0.0001 by two-way ANOVA (n = 5) for all
time points) (Figure 5G).
Moderate increase in collagen levels was observed in
early postnatal DyW development
Picro-Sirius Red staining showed increased fibrotic areas
in DyW mice by week 3 (Figure 6A). At postnatal week 1,
Picro-Sirius Red staining in both DyW and WT mice was
fairly faint, although DyW mice had much greater fibrotic
area in their muscles. To confer further specificity to Sirius
red staining [22], we viewed sections under polarized light
(a method of viewing Picro-Sirius Red–stained thick colla-
gen fibers). Neither DyW nor WT muscles showed a high
presence of collagen fibers at week 1 (data not shown). In
contrast, by week 3, WT muscles exhibited minimal inter-
stitial spaces, whereas age-matched DyW muscles still has
large spaces between fibers that now stained a deep red.
Again, these slides were viewed under polarized light,
which revealed limited amounts of collagen deposition in
the WT muscles, even in those areas stained red, and a
much higher presence in the DyW muscles (data not
shown). We then quantified our results by performing a
hydroxyproline assay (Figure 6B) and found no difference
between DyW and WT hydroxyproline levels at week 1.
By week 2, we saw a 1.3-fold upregulation (P = 0.0001 by
t-test (n = 3)), which was followed by a 2.2-fold increase at
week 3 (P < 0.0001 by t-test (n = 3)), and a 1.5-fold in-
crease at week 4 (P < 0.0001 by t-test (n = 3)). Next, we
looked at the gene expression of Col1a (collagen, type I,
α1) at these four time points (Figure 6C). We saw no
change in transcript levels at week 1, but we saw a signifi-
cant elevation in mRNA expression levels compared to
age-matched WT at 2 weeks (P < 0.001) and 4 weeks (P <
0.05, both by two-way ANOVA) (n = 5). Interestingly, the
largest increase in expression was at postnatal week 2, be-
fore we saw any major increase with hydroxyproline or
Picro-Sirius Red.
Figure 5 Western blot analysis, qRT-PCR and ELISA show increased levels of NFκB–mediated inflammation starting at postnatal week 1
and continuing through development. (A) Western blot of total and phosphorylated p65 reveals that DyW mice had elevated levels of NF-κB
signaling beginning at postnatal week 1 and continuing throughout development. (B) TNF-α gene analysis shows that DyW muscles had
significantly elevated expression at week 1 (P < 0.01), week 3 (P < 0.0001) and week 4 (P < 0.05 by two-way ANOVA (n = 5) for all groups).
(C) Gene expression analysis of MCP-1, reveals that DyW and WT mice had comparable expression levels until postnatal week 4, at which point
the DyW MCP-1 level became significantly elevated (P < 0.0005 by two-way ANOVA (n = 5)). (D) Osteopontin (OPN) was also highly upregulated
(>25 –fold) at every time point (P < 0.0005 by two-way ANVOA (n = 5) for all groups). (E) ELISA of TNF-α shows elevated expression levels in DyW
mice starting at week 2 (P < 0.05 for week 2, P < 0.0001 for weeks 3 and 4, both by two-way ANOVA (n = 3)). (F) MCP-1 was also found to be
upregulated at weeks 2, 3 and 4 (P < 0.0001 by two-way ANOVA (n = 3) for all groups). (G) Osteopontin protein was also seen to be upregulated
at each of the four time points (P < 0.0001 by two-way ANOVA (n = 5)), with the largest increases seen in the first 3 weeks. Asterisks indicate
statistical significance between age-matched DyW and WT, hash tags indicate significant changes within the DyW group and Deltas indicate
significant changes within the WT group. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P< 0.0001. These statistical representations also apply other
symbols (Δ, #).
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Figure 6 Picro-Sirius Red staining, hydroxyproline assay and quantitative RT-PCR show moderately elevated levels of collagen in DyW
muscle. (A) Qualitative analysis of Picro-Sirius Red staining done on frozen muscle sections from Lama2DyW (DyW) and wild-type (WT) animals
during the first 4 weeks after birth shows increased presence of collagen by weeks 3 and 4. (B) Hydroxyproline assay shows significantly elevated
levels of collagen at weeks 2, 3 and 4 (P = 0.0001 at week 2, P < 0.0001 at weeks 3 and 4, all by two-way analysis of variance (ANOVA) (n = 3)). (C)
Quantitative RT-PCR shows similar Col1a (collagen, type I, α1) transcript levels between the two groups at weeks 1 and 3, with DyW mice having
significantly increased expression at weeks 2 and 4 (P < 0.05 for week 4 and P < 0.001 for week 2, both by two-way ANOVA (n = 5 for all groups).
It should be noted that collagen gene expression was extremely variable in both the DyW and WT animals at all time points. Asterisks indicate
statistical significance between age-matched DyW and WT animals, hash tags indicate significant changes within the DyW group and Deltas
indicate significant changes within the WT group. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. These statistical representations also apply
other symbols (Δ, #). Bar = 100 μm.
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TGF-β-mediated fibrosis and ECM remodeling
We next performed Western blot analysis of Smad2/3, a
transcription factor downstream of TGF-β that induces the
expression of collagen and other fibrotic proteins. Although
Western blot analysis showed no increase in total Smad2/3
until week 2, there was a threefold increase in the activated
(phosphorylated) form as early as week 1 (Figure 7A, Full
blot can be found in Additional file 2). Throughout the rest
of development, both total Smad2/3 and phospho-Smad2/3
were upregulated in DyW animals. We also looked at the
expression of Smad7, a protein that inhibits TGF-β signaling
at the level of the receptor as well as in the nucleus [23,24].
We found that, in addition to Smad2/3 being upregulated,
Smad7 expression was decreased at weeks 2 through 4.
We also examined the expression of two other fibrosis-
related genes downstream of TGF-β: fibronectin (Fn1) andperiostin (Postn).WT animals have their highest Fn1 expres-
sion in the first 2 weeks after birth, which is followed by a
significant decrease between weeks 2 and 3 (P < 0.05 by
two-way ANOVA (n= 5)) (Figure 7B). In contrast, though
Fn1 expression in DyW muscles also decreased between
weeks 2 and 3 (P < 0.01 by two-way ANOVA (n = 5)), it in-
creased significantly between weeks 3 and 4 (P < 0.0001 by
two-way ANOVA (n = 5)). At each of these early time
points, Fn1 expression showed a two- to fourfold upreg-
ulation in DyW animals compared to age-matched WT
(P < 0.0001 by two-way ANOVA (n = 5)). Postn was also
upregulated in DyW animals throughout most of devel-
opment (Figure 7C). WT mice had their highest levels
of Postn expression at postnatal week 1, which signifi-
cantly decreased by week 3 (P < 0.0001 by two-way
ANOVA (n = 5)). Like Fn1 expression, expression of
Postn in DyW muscles showed a decrease between
Figure 7 Western blot and quantitative RT-PCR show upregulated extracellular matrix remodeling pathways in DyW mice throughout
postnatal development. (A) Western blot of total and phosphorylated Smad2/3 (pSmad2/3) shows an increase in transforming growth factor β
(TGF-β) signaling as early as week 1. Additionally, we saw a decrease in Smad7 expression as early as week 2. (DyW is also referred to as KO,
Knockout.) (B) Fibronectin 1 (Fn1) gene expression was found to be upregulated two- to fivefold in Lama2DyW (DyW) animals at all four time
points compared to age-matched wild-type (WT) mice (P < 0.0001 by two-way analysis of variance (ANOVA) and n = 5 for all groups). (C)
Additionally, periostin (Postn) transcript levels showed massive upregulation at weeks 2, 3 and 4 (P < 0.05 for week 1, P < 0.005 for week 3
and P < 0.0001 for weeks 2 and 4, all by two-way ANOVA (n = 5 for all groups)). (D) Matrix metalloproteinase 2 (MMP-2) transcription levels
became elevated by postnatal week 2 and remained that way through week 4 (P < 0.0005 by two-way ANOVA (n = 5)). (E) In contrast,
MMP-9 expression was significantly upregulated at weeks 1, 2 and 3 (P < 0.005 by two-way ANOVA (n = 5)), but was comparable to the WT
by week 4. (F) Gene expression of tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) shows a several-fold upregulation starting as early
as week 1 (P < 0.0005 by two-way ANOVA (n = 5)). Asterisks indicate statistical significance between age-matched DyW and WT animals, hash
tags indicate significant changes within the DyW group and Deltas indicate significant changes within the WT group. *P < 0.05, **P < 0.01,
***P < 0.001 and ****P < 0.0001 These statistical representations also apply other symbols (Δ, #).
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followed by an upregulation between weeks 3 and 4
(P < 0.01 by two-way ANOVA (n = 5)). At all time
points, DyW mice had significantly increased expression
in POSTN compared to age-matched WT mice (P < 0.05
at week 1, P < 0.0001 at weeks 2 and 4 and P < 0.005 at
week 3, all by two-way ANOVA (n = 5)).
We found that the gene expression of matrix metallo-
proteinases (MMPs) 2 and 9, proteins that participate in
the degradation of collagen and other (ECM) compo-
nents [24,(25], were upregulated in DyW muscles
throughout development. Expression of MMP-2 in WT
muscles began high and decreased with age, becoming
significantly lower by week 3 (P < 0.001 by two-way
ANOVA (n = 5)) (Figure 7D), whereas MMP-9 showed no
fluctuation over time (Figure 7E). In DyW mice, MMP-2
expression was consistent at weeks 1 through 3 and in-
creased significantly by week 4 (P < 0.0001 by two-way
ANOVA (n = 5). MMP-9 expression, on the other hand,Figure 8 Qualitative analysis of fibronectin 1–stained frozen tibialis a
weeks 1 through 4. (A) Qualitative analysis shows that the highest levels of
have occurred at postnatal week 1. WT, Wild type. (B) Quantification using flu
shows that DyW mice have elevated fibronectin expression at each time poin
fibronectin remained persistently upregulated throughout postnatal developmwas at its highest early on and decreased between weeks 2
and 3 (P < 0.05 by two-way ANOVA (n = 5). In comparison
to age-matched WT mice, in DyW mice, MMP-2 was
found to be significantly upregulated at weeks 2, 3 and 4
(P < 0.0005 by two-way ANOVA (n = 5)), and MMP-9 was
found to be overexpressed at weeks 1, 2 and 3 (P < 0.005 by
two-way ANOVA (n = 5)). Interestingly, tissue inhibitor of
matrix metalloproteinase 1 (TIMP-1) was also upregulated
at every time point (P < 0.0005 by two-way ANOVA (n =
5)) and to a much greater degree than either MMP-2 or
MMP-9 (Figure 7F). We saw no significant TIMP-1 fluctu-
ations inWT animals.
Immunohistochemistry shows increased presence of
fibronectin as early as postnatal week 1
Immunostaining with fibronectin antibodies revealed that,
as early as postnatal week 1, there was an extremely in-
creased presence of fibronectin in the interstitial spaces of
DyW animals compared to the WT (Figure 8A). Wenterior muscle sections from DyW and WT mice at postnatal
fibronectin in the extracellular matrix of Lama2DyW (DyW) mice appear to
orescence thresholding confirms the immunohistochemical results and
t (P < 0.01 by t-test (n = 3)). Though this expression decreased with age,
ent. Bar = 50 μm.
Figure 9 Quantitative RT-PCR of angiotensin-related genes shows dysregulation of the renin-angiotensin signaling system in DyW
muscle. (A) Gene analysis of angiotensin (Agt) shows no difference in expression between Lama2DyW (DyW) and wild-type (WT) animals from
postnatal weeks 1 through 4. (B) We found that angiotensin-converting enzyme (Ace) was significantly upregulated by week 3 (P < 0.005, by
two-way analysis of variance (ANOVA) (n = 5)). (C) Angiotensin II type 1a receptor (Agtr1a) was also upregulated starting at week 3 in these mice
(P < 0.001 by two-way ANOVA (n = 5). (D) We found that the expression of angiotensin II type 2 receptor (Agtr2) was increased several-fold over
the WT mice starting at week 2 (P < 0.0001 by two-way ANOVA (n = 5)). Note that, though it does not entirely come across in the graph, there is
a 25-fold increase in Agtr2 expression at week 4. Asterisks indicate statistical significance between age-matched DyW and WT animals, hash tags
indicate significant changes within the DyW group and Deltas indicate significant changes within the WT group. *P < 0.05, **P < 0.01, ***P < 0.001
and ****P < 0.0001. These statistical representations also apply other symbols (Δ, #).
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sities using a predetermined threshold. These data show
that, at postnatal week 1, 40% of total DyW muscle area
exhibited fibronectin staining above a given fluorescence
threshold, compared to approximately 1% in the WT (P <
0.001 by t-test (n = 3)) (Figure 8B). The signal intensity
remained higher in the DyW animals at each time point,
though it was definitely most pronounced in the first
3 weeks after birth (P < 0.01 by t-test (n = 3).qRT-PCR shows dysregulation of angiotensin system by
week 2
Overexpression of angiotensin has recently been impli-
cated to drive both inflammation and fibrosis through the
NF-κB and TGF-β pathways, respectively [25-27]. We saw
that DyW mice had no significant differences in angioten-
sin expression compared to age-matched WT through
week 4 (Figure 9A). Although WT levels of angiotensin-
converting enzyme (Ace) did not fluctuate over time, DyW
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by two-way ANOVA (n = 5)) (Figure 9B). Additionally,
angiotensin II receptor type 1a (Agtr1a) and type 2 (Agtr2)
in the WT had high expression early in development,
which then decreased with time. DyW mice showed a
similar pattern, but failed to achieve this same decrease in
expression, leading to a significant overexpression of Agtr1a
at weeks 3 and 4 (P < 0.001 by two-way ANOVA (n = 5))
(Figure 9C) and of Agtr2 at weeks 2, 3 and four (P < 0.0001
by two-way ANOVA (n = 5) (Figure 9D). We would like to
note that, though the extent of upregulation of Agtr2 at
week 4 does not come across on the graph in Figure 9D,
DyW mice had a 20-fold increase compared to age-
matchedWT animals.
Discussion
Patients with MDC1A have been shown to exhibit im-
paired muscle growth and progressive inflammation,
followed by extensive fibrosis very early in life [28,29]. We
observed that DyW and WT mice have comparable body
and muscle weights at week 1, only becoming drastically
different by week 3, when WT mice began a large growth
spurt that was lacking in DyW animals. Although an overt
phenotype was not apparent at week 1, our observations
at the cellular level reveal that pathology was already ram-
pant. Our histological analysis shows that, even though
muscle CSAs were comparable at week 1, only a small
proportion of DyW muscle tissue was actually occupied by
myofibers, with the rest of the muscle being taken up by
large interstitial spaces that contained a high number of
mononucleated cells and fibrillar proteins. In fact, as early
as week 1, DyW muscles contained only half the number
of myofibers as theirWT counterparts.
We believe that the decreased number of myofibers
present in these muscles is partly explained by either im-
paired myogenesis or increased muscle degeneration. We
found that DyWmice exhibited high numbers of apoptotic
nuclei throughout early development. This is in congru-
ence with the findings in other laboratories in which re-
searchers have shown massive muscle fiber degeneration
early in the pathology of patients with MDC1A as well as
in DyW, dy/dy and Dy3K mice [14-16,18]. Our data also
show that DyW muscles upregulated the expression of
myogenic genes, including eMYHC, likely in an attempt
to compensate for this loss of fibers. Wardrop and Domi-
nov [17] also noted an elevation of eMYHC protein in
DyW mice, and Reggianni et al., who also saw this in the
dy/dy model, argued that this is an indicator of delayed
differentiation in laminin-deficient muscles [30]. Further,
it has previously been demonstrated that partially differen-
tiated myofibers are prone to apoptosis [31], and it has
been suggested that the lack of regeneration seen in
laminin-deficient mice is actually due to the death of
newly formed myofibers [32,33]. In line with thesehypotheses, we saw the largest presence of apoptotic nu-
clei in DyW mice at postnatal week 1, the time point when
these mice would have the largest number of newly
formed fibers. In fact, at earlier time points we saw many
small desmin-positive cells in the interstitium undergoing
apoptosis, which was less prevalent at later time points.
Our results suggest that, though antiapoptotic therapies
could be useful throughout the lives of these mice, they
may have the greatest efficacy very early in postnatal de-
velopment by helping to preserve the population of devel-
oping myofibers. We have demonstrated that genetic
inhibition of apoptosis by mutation of the BAX gene in
these mice results in the most robust outcome of all apop-
totic therapies that have been tried in this disease [34,35].
We believe that, because of the extracellular origins of
this disease, abnormalities in the myomatrix [36] and extra-
cellular environment of these mice are paramount to the
progression of DyW pathology. Our unpublished results
and the work of investigators in other laboratories actually
show that laminin-deficient muscles have dysregulation of
matricellular proteins, molecules that are structurally unre-
lated components of the extracellular matrix that, under
normal circumstances, are elevated only in development or
in response to injury [13,17]. These matricellular proteins,
such as tenascin C and thrombospondins, along with vari-
ous cytokines, growth factors and cell surface receptors,
play a major role in signaling and tissue remodeling in
pathological scenarios [37,38]. In this study, we provide a
comprehensive set of novel results focused on the expres-
sion of a few such molecules in DyWmice, including osteo-
pontin, periostin, and fibronectin, that may help to explain
the link between inflammation and pathological tissue re-
modeling in this disease.
It has been established that chronic inflammation in-
hibits muscle regeneration, promotes apoptosis and leads
to the dysregulation of matricellular proteins [39-42]. In-
deed, researchers at various laboratories have shown that
inflammation is one of the earliest pathologies seen in
many dystrophies, including in patients with MDC1A
[18,43]. Here we show that laminin-deficient muscles have
a high infiltration of macrophages from a very early age,
which remains a persistent issue throughout development.
These findings are coincident with increased NF-κB sig-
naling and upregulation of NF-κB related cytokines, all of
which are known to promote inflammation, inhibit myo-
genesis and increase protein degradation [42,44,45]. What
is particularly interesting about our findings is the massive,
persistent transcriptional dysregulation of osteopontin in
the first 4 weeks after birth. Osteopontin is an adhesive
ECM protein that also plays a large role in integrin-
mediated cell signaling and can be secreted by both regen-
erating muscle and macrophages [46,47]. It has been
shown that certain base levels of osteopontin can promote
muscle regeneration and recruit macrophages in response
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pontin inhibit myogenesis and promote chronic inflamma-
tion and TGF-β-mediated fibrosis [47-50]. Therefore, it is
plausible that osteopontin plays a major role in initiating
chronic inflammation in DyW mice and recruiting im-
mune cells to interstitial spaces during development, as
well as in inhibiting early myogenesis, and paves the way
for the onset of fibrosis.
In contrast to many other dystrophies, such as DMD, fi-
brosis appears to be a very early hallmark of MDC1A. Early
increases in TGF-β signaling, a cytokine known to promote
fibrosis and inhibit myofiber differentiation [51,52], implies
that fibrotic signaling has begun no later than week 1. Inter-
estingly, though collagen expression was not greatly in-
creased until week 3, we found that periostin, another
adhesive molecule of the ECM and downstream target of
TGF-β, was upregulated as early as week 1. Periostin is
produced by fibroblasts in non–disease scenarios and,
when ablated, leads to a greatly improved fibrotic pheno-
type in mdx mice [53-55]. Thus, though collagen may not
be elevated very early on, other fibrotic components of the
TGF-β pathway may have already taken hold. Of note, the
highest levels of periostin overexpression are coincident
with the greatest increases in collagen protein. This is par-
ticularly interesting because periostin has been implicated
in promoting collagen fibrillogenesis [56].
Further, we found that, at week 1, there was a large up-
regulation of fibronectin on both the gene and protein
levels. It has previously been demonstrated that macro-
phages are actually capable of secreting fibronectin [57,58].
It has also been shown that fibronectin acts as a substrate
for the migration of fibroblasts into tissues [58]. This is of
particular importance in MDC1A because it gives rise to
the possibility that the initiation of fibrosis and matrix dys-
regulation might be a direct result of the inflammatory na-
ture of this disease. Additionally, Ross et al. demonstrated
that satellite cells exposed to increased levels of fibronectin
display a reduced proliferative capacity [59]. Thus, in
addition to the potential of inhibited myogenesis due to
early TGF-β signaling and large spaces of nonfunctional
muscle, the substrate on which these muscle cells lie is in-
nately less conducive to regeneration.
We also found that MMP-2 and MMP-9, collagenases
that could help compensate for fibrotic buildup by in-
creasing protein turnover of collagen and fibronectin,
were upregulated at different time points in develop-
ment. TIMP-1, an inhibitor of these molecules [60], was
also upregulated, and to a much larger extent than either
MMP, at all time points. These results were likely caused
by one of two scenarios: Either the expression and activ-
ity of MMPs was being upregulated to compensate for
increased fibrosis, subsequently leading to an increase in
TIMP-1 through negative feedback, or MMP gene ex-
pression was upregulated as a response to decreasedMMP activity, which was supported by the much larger
increases in TIMP-1 expression. Even though we cannot
know which scenario is more likely without performing
an additional assay, such as zymography [61], these data
further show that nearly all facets of the myomatrix in
these mice were dysregulated from a very early age.
Last, in recent years, the renin-angiotensin signaling
system has become increasingly understood to be intim-
ately connected with the dysregulation of inflammation,
fibrosis and ECM remodeling in many disease scenarios
[27,62-64]. In this study, we found that, although the
angiotensin gene itself was not dysregulated in DyW
mice, Ace and two of its receptors were overexpressed
very early on. It has been shown previously that blocking
angiotensin II signaling with losartan can greatly im-
prove the fibrotic DyW phenotype [64,65]. Additionally,
losartan and other angiotensin receptor blockers have
been shown to reverse the buildup of fibronectin and de-
crease the expression of various other matricellular pro-
teins that we have shown to be dysregulated in DyW
mice. Although losartan has been shown to have mixed
results in the context of DMD, its impressive efficacy in
models of MDC1A is likely due to the early dysregula-
tion of fibrotic pathways in laminin deficiency.
Conclusion
In order to properly assess and treat diseases with devel-
opmentally complex, evolving pathologies, we must study
them in a temporal fashion so that we can identify the
relevance of various pathomechanisms at different points
in the disease progression. This will allow us to identify
appropriate time windows to implement therapies targeting
each of these pathologies that may be critical to their effi-
cacy. Using the DyW mouse model, in this study, we pro-
vide novel insight into the development of pathologies in
MDC1A and reveal that, as opposed to classical dystrophies
such as DMD, the dysregulation of numerous matricellular
proteins is a very early signature of laminin-deficient path-
ology. We also demonstrate that antiapoptotic, promyo-
genic and antifibrotic therapies could benefit patients most
if started at a very early age. The aims of further studies that
might lead to better therapies for this patient population
should include determination of whether interventions that
target specific pathomechanisms need to be lifelong or
whether they could be restricted to given time windows
during disease progression.
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